Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

BridgeBio announced positive Phase 3 CALIBRATE trial results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), showing 91% of participants achieved normal PTH levels compared to 0% on standard care, with 100% reporting symptom improvements versus 46% on conventional therapy. The FDA accepted the NDA with Priority Review (PDUFA date May 8, 2027), and the company initiated the Phase 3 RECLAIM-HP trial for chronic hypoparathyroidism.